LOS ALTOS, Calif., January 25, 2017 -- Globavir Biosciences, Inc., a California-based biotechnology company developing dengue diagnostics and small molecule drugs to treat cancer and infectious diseases, has announced the approval of their PanGlob™ Dengue rRT-PCR kit from the Ministry of Health & Family Welfare in India.
LOS ALTOS, Calif., Oct. 17, 2016 /PRNewswire/ -- Globavir Biosciences, Inc., a biotechnology company that develops therapeutics for infectious diseases and oncology, and diagnostics for infectious diseases, announced a partnership with Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostics products.
LOS ALTOS, Calif., July 9, 2015 /PRNewswire/ -- Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an oncology company developing new treatments for cancer and associated pain,
Globavir Biosciences Inc has recently been accepted into Stanford University's StartX Med Accelerator for the Fall 2014/Winter 2015 cohort. StartX is based in the heart of Silicon Valley and is one of the most prominent and exclusive technology accelerators in the world, historically accepting approximately 8% of Stanford affiliated applicant companies.